LAT1
Ongoing clinical trials and approved products targeting LAT1, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.
2ongoing therapy trials
0ongoing imaging trials
0approved products
Target note
- Full name
- L-type neutral amino acid transporter (LAT1, SLC7A5)
- Nature
- Membrane transporter of essential amino acids, overexpressed by proliferating cells.
- Normal expression
- Blood–brain barrier, placenta, kidney.
- Disease expression
- High-grade gliomas, many highly proliferative cancers.
- Value
- Crosses the blood–brain barrier: access to gliomas.
- Approaches
- ¹³¹I-iodophenylalanine (TLX101).
- Indications explored
- Newly diagnosed or recurrent glioblastoma, combined with radiotherapy (phase 3 ongoing).
- Points of caution
- Radiation protection linked to ¹³¹I; thyroid blocking.
| Trial | Phase | Status | Sponsor | Countries |
|---|
| IPAX BrIGHT · [131I]IPA (TLX101)NCT07100730 · Brain (glioma, medulloblastoma…) | Phase 3 | Recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 4 |
| IPAX-2 · [131I]IPA (TLX101)NCT05450744 · Brain (glioma, medulloblastoma…) | Phase 1 | Active, not recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 3 |
Cite this page
LAT1. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/lat1/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.